
usd pm et
summari merck one world lead biopharmaceut compani well produc
vaccin anim health medic
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
acceler growth
period immuno-oncolog drug
keytruda sale yoy continu
lead way reach annual
keytruda tremend success
treatment made standard care
growth along strong vaccin portfolio
sale yoy
gain lung cancer continu drive
near-term growth longer term expans
 approv kidney
head-and-neck cancer obtain
global market respect
see slower growth pace keytruda
current though due matur
rapid uptak lung cancer
treatment lung second common
type cancer global market
mean new indic like
fuel keytruda vaccin demand ytd
growth remain thru least
potenti upsid bridion sale
expect see materi acceler
revenu growth robust
demand keytruda favor patent
market exclus setup annual
revenu growth averag
period saw three former top
drug undergo major sale declin due
gener biosimilar entri look forward
see favor patent setup key
brand lose market exclus
growth engin keytruda patent
expect keytruda continu grow
rapidli uptak exist cancer
indic like lung melanoma kidney
well potenti longer term approv
major indic breast colon
ketyruda tremend success
pair stabl revenu rest
portfolio see healthi runway
double-digit ep growth thru least
target price ep
estim forward price-to-earnings
averag due acceler growth risk
view includ pipelin failur
lower-than-expect market share
keytruda vaccin potenti new
 regul drug price
subject intens competit treatment
market share brand-nam drug also face
risk gener biosimilar maker market
copi brand challeng patent court
flood market patent expir also risk
associ drug failur clinic trial regulatori
approv hurdl potenti unfavor price
patent regul hand govern
risk balanc valuabl franchis
immuno-oncolog vaccin drug
experi persist demand due industri lead
feb ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview merck co lead global drugmak produc wide rang
prescript drug vaccin mani therapeut area abroad largest
market account total revenu europ middl east africa second
largest
top-sel product includ keytruda cancer sale januvia/janumet type
hiv/aid bridion revers neuromuscular block agent pneumovax pneumococc
vaccin simponi arthritis/immunolog
addit human pharmaceut vaccin also anim health segment
sale anim health develop market pharmaceut vaccin product prevent
treatment control diseas major livestock companion anim speci
keytruda top-sel drug keytruda primari driver behind earn growth sinc
cancer drug first approv fda septemb second-lin treatment
first treatment option fail melanoma held long-stand strategi expand
indic keytruda lucr first-lin treatment set prescript
written cancer largest patient popul success
strategi ketyruda gain approv broad rang cancer indic sever
first-lin treatment set februari keytruda fda approv indic includ among
other first-lin treatment non-smal cell lung cancer nsclc combin chemotherapi
singl agent first-lin treatment nsclc patient specif tumor express second-lin
treatment head neck squamou cell cancer second-lin treatment cervic cancer
second-lin treatment hepatocellular liver cancer
keytruda gain first-lin nsclc indic due lung second-most common
type cancer achiev major mileston drug keytruda success indic
expans fuel tremend sale growth million billion
expect keytruda gain addit first-lin indic includ renal cell carcinoma kidney
cancer head neck cancer keytruda also on-going phase clinic trial mani type
cancer like continu drive robust growth sever year includ phase trial
breast prostat colorect cancer among common type cancer
behind lung term frequenc
one drag keytruda futur sale growth outcom patent disput relat drug
biolog formul januari enter settlement licens agreement resolv
world-wide patent infring litig relat keytruda pursuant settlement compani
pay royalti net sale keytruda net sale keytruda
market profil world-wide total prescript drug sale project grow compound annual
growth rate compound-annual-growth-rate period accord forecast evaluatepharma
key driver growth age develop popul especi babi
boomer age prime year health care need emerg market like see materi faster
growth prescript sale develop market howev due view
emerg market demand pharmaceut spur rise standard live global middl
class expand gain access advanc health care develop market govern
increas spend health care
financi trend total revenu grew billion billion three-year
compound-annual-growth-rate adjust expens total billion sale
sale adjust ep increas repres three-year
compound-annual-growth-rate key driver faster growth adjust ep revenu share
repurchas activ compani made net repurchas neg impact new share
issuanc billion billion believ conserv capit
earn interest tax amort ebita cover net interest expens roughli time
execut vice-president global
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
neutral sinc novemb technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook sub-industri
next year neutral expect
modest revenu growth driven
slowdown novel drug approv
potenti new price regul
neg partial off-set upcom
favor period patent expir
also expect major gener maker continu
struggl lower cost foreign competit
keep pressur profit margin
banner year new brand
drug fda see slowdown
total novel drug
approv fda
signific surg compar approv
new brand help drive
ebitda growth sub-industri
versu averag
new drug launch appear
slow howev
approv year august
period also observ
yoy declin spend
like portend effort maintain margin
sluggish revenu growth year ahead
pharmaceut also face increas risk
new drug price rule view
accord wall street journal studi
govern health system develop
countri like england norway canada
often pay less major drug
poll indic american feel drug
cost unreason believ
dynam increas pressur drug
maker curtail price hike politician
enact polici lower drug cost
voter accordingli sever new propos
lower drug price emerg side
isl recent month trump
administr announc explor base
medicar drug price intern index
hous democrat introduc bill
would allow medicar directli negoti
price drug maker senat
republican propos lower
out-of-pocket maximum medicar drug
plan shift cost burden
drug maker none propos
current enough support becom law
view see polit parti
increas focu control drug cost
signific risk weigh outlook
sub-industri
balanc neg factor face
brand drug maker expect
upcom favor period patent
expir typic biggest
revenu headwind base data
evaluatepharma annual global drug sale
risk expir patent averag
total forecast
drop fewer
patent cliff year ahead
major posit brand drug revenu
beyond brand firm make lion
share sub-industri market cap outlook
major gener maker neg think
india-bas gener maker continu
take market share develop nation
firm due lower product cost
estim india-bas produc oper
averag gross margin
versu top western gener
foreign firm
drop broader composit
year-to-d septemb
pharmaceut index
gain
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
-- roughli line histor forward price-to-earnings averag lift ep
estim keep ep vs beat
consensu sale rose yoy fastest quarterli growth sinc
perform led strong demand keytruda cancer sale
grew sale yoy keytruda growth trajectori remain strong
view especi new indic approv kidney cancer
adjuv melanoma lung cancer europ china
exclud keytruda sale slightli yoy strength vaccin
sale yoy off-set older drug januvia
yoy primari oper incom grew yoy faster sale strong
sg perform fell yoy expect stellar keytruda growth
continu think share near fair valu /colin scarola
et cfra keep hold opinion share merck co inc
lift target ep estim --
roughli line histor averag forward price-to-earnings lower
ep estim start ep vs
beat consensu sale rose yoy led growth
oncolog drug keytruda total revenu quarter fda
approv keytruda part combin therapi broadli
appli treat certain form lung cancer major mileston
expect new indic maintain keytruda robust
sale growth year ahead outsid keytruda sale declin yoy
howev make increasingli depend premier drug growth full
year adjust pre-tax incom increas increas
expect stellar keytruda growth continu think share
near fair valu given lacklust growth rest drug portfolio
analyst research note compani news
et cfra rais opinion share merck co inc
strong buy buy lift target
ep estim -- forward price-to-earnings averag due
acceler growth rais ep estim
start ep vs yoy
beat consensu revenu adjust ep beat consensu estim
respect power lead drug keytruda cancer
sale saw sale increas yoy sinc approv
keytruda fast becom doctor standard care non-smal
cell lung cancer global market rapidli gain market
share outsid yoy intern growth addit
stretch neg growth ex-keytruda revenu
pace grow driven strong demand critic vaccin
continu think share under-valued base strong growth
trajectori rise oper leverag /colin scarola
et cfra maintain buy opinion share merck co inc
keep target price ep estim
-- histor forward price-to-earnings averag due acceler growth
rais ep estim ep
vs beat consensu revenu grew yoy
fastest growth sinc becom familiar lead cancer drug
keytruda sale led way yoy sale growth reach
annual drug continu gain momentum major indic
includ non-smal cell lung kidney cancer revenu growth also
benefit improv non-keytruda portfolio grew yoy
straight quarter declin due loss exclus former
key drug continu strong growth outlook due momentum
oncolog favor market exclus setup rest
portfolio think justifi materi valuat premium histor
pm et cfra maintain buy opinion share merck co inc
lift price target
ep estim -- five-year forward price-to-earnings averag due
acceler growth rais ep estim
annual revenu growth averag
period saw three -- zetia remicad vytorin -- former top
drug undergo major sale declin due competit gener
biosimilar entri drug gener revenu
look forward see favor patent
market exclus setup expect annual revenu growth
averag think faster growth outlook compar
previou five-year averag justifi materi valuat premium
et cfra upgrad opinion share merck co inc buy
hold lift target
ep estim -- five-year forward price-to-earnings averag due acceler
growth organ sale growth best histori
yoy rapidli acceler full-year keytruda
revenu continu deliv sale yoy also note
rest portfolio stabil see sale declin
three year expect keytruda continu grow rapidli share gain
larg popul includ line lung cancer melanoma import
new indic includ april approv line kidney cancer
tremend growth potenti set backdrop stabl
revenu rest portfolio think ep growth averag
next three year versu valuat near
five-year averag despit acceler growth expect share
et cfra keep hold opinion share merck co inc
lift target ep estim
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
